Meeting
2023 ASCO Annual Meeting
Next generation sequencing reveals targetable mutations in multiple sarcoma histologies.
Authors
Rodney Dixon Dorand Jr.
Vanderbilt-Ingram Cancer Center, Nashville, TN
Rodney Dixon Dorand Jr., Michael Robinson , Lauren King , Emma A. Schremp , Adam Xavier Miranda , Juan M Colazo , Ben Ho Park , Leo Y Luo , Xiao-Ou Shu , Tuya Pal , Debra L. Friedman , Elizabeth J. Davis
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Molecular Targets/Biomarkers/Tumor Biology
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 11548)
DOI
10.1200/JCO.2023.41.16_suppl.11548
Abstract #
11548
Poster Bd #
482
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Seventeen percent of NGS 50 gene panel variants are not expressed in RNAseq.
First Author: Razelle Kurzrock
Poster
2020 ASCO Virtual Scientific Program
NCI protocol 10250: A phase II study of temozolomide and olaparib for the treatment of advanced uterine leiomyosarcoma.
First Author: Matthew Ingham
Poster
2024 ASCO Genitourinary Cancers Symposium
Malignant epithelioid angiomyolipoma (eAML)/PEComa of the kidney: A genomic landscape study.
First Author: Rebecca A Sager
Poster
2023 ASCO Annual Meeting
Frequency and spectrum of clinically significant molecular alterations detected by tumor gene panel testing for pediatric cancer patients in the Texas KidsCanSeq study.
First Author: Frank Y. Lin